FDA approves Spiriva HandiHaler for COPD
The US FDA has approved Boeringer Ingelheim's Spiriva HandiHaler (tiotropium bromide inhalation powder) for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
The US FDA has approved Boeringer Ingelheim's Spiriva HandiHaler (tiotropium bromide inhalation powder) for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Spiriva was discovered and developed by Boehringer Ingelheim and will be co-promoted in the US with Pfizer.
It is expected that Spiriva will be available in US retail pharmacies by the middle of this year. It has been launched in more than 40 countries, and further approvals are expected in 2004 and 2005.